Biogen (BIIB) announced Thursday that the US Food and Drug Administration has accepted its supplemental new drug application and that the European Medicines Agency has validated the application for a higher dose regimen of its experimental drug, nusinersen, for spinal muscular atrophy.
The company said it would study the efficacy of a higher dose regimen, including two 50 mg doses given 14 days apart and a maintenance dose of 28 mg every four months, compared to the currently approved regimen.
Nusinersen, marketed as Spinraza, is available in over 71 countries at the approved 12 mg dose, it added.
Biogen licensed the global rights to develop and commercialize Spinraza from Ionis Pharmaceuticals (IONS).
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。